Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Florbetaben F18 - Piramal

Next Previous
Drug Profile

Florbetaben F18 - Piramal

Alternative Names: 18F-AV 1; 18F-AV1/ZK; [18F] florbetaben; AV-1; AV-1/ZK; BAY 94-9172; Florbetaben 18F; florbetaben18F; NeuraCeq; Neuraceq; UNII-TLA7312TOI; ZK 6013443

Latest Information Update: 19 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Avid Radiopharmaceuticals
  • Developer Avid Radiopharmaceuticals; Bayer HealthCare Pharmaceuticals; Ci-Co Healthcare; FONDAZIONE TOSCANA GABRIELE MONASTERIO; Isologic Innovative Radiopharmaceuticals; PET Pharm Biotech; Piramal Enterprises; Sinotau Pharmaceuticals
  • Class Aniline compounds; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Alzheimer's disease
  • Phase III Amyloidosis
  • Phase II Cardiovascular disorders
  • Discontinued Mild cognitive impairment

Most Recent Events

  • 13 Dec 2023 Launched for Alzheimer's disease (Diagnosis) in Japan (IV)
  • 13 Dec 2023 Japanese Ministry of Health approves the reimbursement by governmental health insurance of the amyloid Positron Emission Tomography (PET) diagnostic Neuraceq® (florbetaben 18F)
  • 22 Nov 2023 Registered for Alzheimer's disease (Diagnosis) in Japan (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top